Berenberg Bank Increases Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 2,100

Hikma Pharmaceuticals (LON:HIK) had its price target raised by Berenberg Bank from GBX 2,000 ($25.54) to GBX 2,100 ($26.81) in a report published on Monday morning, MarketBeat reports. Berenberg Bank currently has a hold rating on the stock.

HIK has been the subject of several other reports. Barclays reiterated an equal weight rating and issued a GBX 2,000 ($25.54) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft reiterated a buy rating and set a GBX 2,750 ($35.11) price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of GBX 2,250 ($28.73).

Hikma Pharmaceuticals Stock Performance

HIK stock opened at GBX 2,074 ($26.48) on Monday. The company has a market capitalization of £4.60 billion, a P/E ratio of 3,095.52, a PEG ratio of 2.38 and a beta of 0.40. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The company has a 50-day simple moving average of GBX 1,909.02 and a 200 day simple moving average of GBX 1,914.20. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,711 ($21.85) and a fifty-two week high of GBX 2,216 ($28.29).

Hikma Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 15th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a yield of 1.37%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is 9,402.99%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.